Literature DB >> 10759903

Patients with acenocoumarol treatment and migraine.

F Morales-Asín1, C Iñiguez, R Cornudella, J A Mauri, F Espada, E E Mostacero.   

Abstract

OBJECTIVE: The aim of our study was to investigate the possible effect of acenocoumarol, which is indicated for nonneurological disease, on headache.
BACKGROUND: It has been suggested that anticoagulation can have beneficial effects in the control of migraine attacks.
METHODS: Four hundred randomized patients on oral anticoagulant therapy were asked to complete a questionnaire regarding their headaches.
RESULTS: Headache was present before or during oral anticoagulation in 166 (66 migraineurs and 100 nonmigraineurs) of 326 respondents. The major finding was that oral anticoagulation produced improvement in 63% of patients with migraine versus 38% of patients with nonmigranous headache. Improvement was related to the severity of migraine but not to age.
CONCLUSIONS: Oral anticoagulant therapy can improve migraine. The way in which anticoagulant therapy acts on migraine is unknown, but potential mechanisms include its effect on platelet aggregability and pharmacological effects such as suppression of enhanced nitric oxide.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10759903     DOI: 10.1046/j.1526-4610.2000.00008.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  2 in total

1.  Migraine responsive to warfarin: an update on anticoagulant possible role in migraine prophylaxis.

Authors:  F Maggioni; M Bruno; F Mainardi; C Lisotto; G Zanchin
Journal:  Neurol Sci       Date:  2012-01-06       Impact factor: 3.307

Review 2.  Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria?

Authors:  Mohammad Hassan A Noureldine; Ali A Haydar; Ahmad Berjawi; Rody Elnawar; Ahmad Sweid; Munther A Khamashta; Graham R V Hughes; Imad Uthman
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.